Shenyang Xingqi Pharmaceutical Co Ltd

Shenyang Xingqi Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 1.86, indicating the company can cover its short-term liabilities with its short-term assets. The company's debt-to-equity ratio is 0.05, suggesting a conservative capital structure with minimal reliance on debt financing. However, the company has a negative net cash position after subtracting total debt, which raises some liquidity concerns. In terms of profitability, the company's return on equity (ROE) is 35.18%, and its return on assets (ROA) is 27.41%, both of which are strong indicators of efficient use of equity and assets to generate profit. These figures are well above the typical thresholds for the pharmaceutical industry, suggesting that the company is performing better than the median in its sector. The company's revenue is concentrated in a single business segment, as disclosed in its financial reports, with no material geographic diversification beyond the Chinese market. This concentration increases the company's exposure to domestic economic and regulatory changes, which could impact its revenue stability. Looking at the company's growth trajectory, there is no explicit guidance provided for the current or next fiscal year. However, the company's operating cash flow of 753.39 million CNY and free cash flow of 186.00 million CNY suggest a healthy cash-generating business. The capital expenditure of -270.53 million CNY indicates that the company is not currently investing heavily in new projects or infrastructure. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The risk assessment highlights the negative net cash position as a key flag, which could affect the company's ability to meet short-term obligations without external financing. The dilution risk is low, and there is no indication of near-term dilution pressure from recent filings or disclosures. Recent events and filings do not indicate any major corporate actions or strategic shifts. The company's ESG profile is strong, with a governance pillar score of 86.47 and a social pillar score of 52.11, indicating a relatively responsible approach to corporate governance and social issues. The ESG controversies score of 100.00 suggests that the company has not been involved in any significant ESG-related controversies.